UNSPSC 51111753: Mitoguazone

This classification denotes a s-adenosyl-methionine decarboxylase inhibitor and polyamine inhibitory agent with the molecular formula C5H12N8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OD5Q0L447W, chemically known as 1,1-((methylethanediylidene)dinitrilo)diguanidine but generally known as mitoguazone, which bears US NIH Compound Identifier 5351154. European Medicines Agency schedules Mitoguazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09004MIG.

UNSPSC 51111753 Mitoguazone, a Commodity code, describes pharmaceutical products procured by state and local health agencies, though recent solicitations tagged to this code show limited direct activity specific to mitoguazone itself and instead reflect broader pharmaceutical and medical supply purchasing patterns. State and local governments acquiring under this code and related pharmaceutical commodity codes procure naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and emergency medical supplies through health departments, fire rescue divisions, and health and human services commissions. Soliciting bodies span county health agencies, municipal fire departments, state HHS commissions, and cooperative purchasing alliances. The procurement vehicles vary from competitive sealed bids (IFB) to requests for proposal (RFP) for multi-year supply contracts, often with quarterly or continuous delivery schedules and fixed-fee or competitive pricing models. Most contracts require vendors to maintain specific insurance coverage, comply with federal drug supply chain regulations such as the Drug Supply Chain Security Act, and provide products with extended shelf life and expiration-date requirements.

Recent activity appears concentrated in Florida and Minnesota, with additional state-level engagement in Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with delivery to the Seminole County Community Health Building and a response deadline of July 26, 2023. The City of Tampa Purchasing Department released an IFB (26P00145) in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, designated as sheltered market for certified Small Local Business Enterprises with an estimated contract value of $700,000, with responses due March 13, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission posted an exploratory RFI (HHS0017013) in April 2026 regarding a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, signaling future state-level pharmaceutical procurement strategy development.